LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

Home・Aktien・Karyopharm Therapeutics Inc

Karyopharm Therapeutics Inc

Open

Branche Gesundheitswesen

0.97

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

0.93

Max

1.05

Schlüsselkennzahlen
By Trading Economics
Verkäufe	34M
EPS	-0.36
Angestellte	325

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+415.48 upside

Dividenden
By Dow Jones
Nächstes Ergebnis	5. Nov. 2024

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	1.2M 154M
Vorheriger Eröffnungskurs	0.97
Vorheriger Schlusskurs	0.97

Nachrichtenstimmung

By Acuity

30%

70%

93 / 389 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bullish Evidence

0.8423 / N/A Unterstützung & Widerstand

Karyopharm Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

31. Okt. 2024, 23:57 UTC

Heiße Aktien

Stocks to Watch: Intel, Amazon.com, Abbott Laboratories, MasTec

31. Okt. 2024, 23:43 UTC

Ergebnisse

Bud Light Owner's U.S. Sales Bounce Back After Boycott -- 4th Update

31. Okt. 2024, 23:14 UTC

Wichtige Markttreiber

Abbott Laboratories Shares Rise After Baby-Formula Verdict

31. Okt. 2024, 23:04 UTC

Top News

Australian Manufacturing Activity Edges Up From Recessionary Lows

31. Okt. 2024, 22:44 UTC

Ergebnisse

Macquarie Lifts Dividend, Extends Buyback After 1st Half Profit Rises -- Update

31. Okt. 2024, 22:14 UTC

Ergebnisse

Macquarie Lifts Dividend, Extends Buyback After 1st Half Profit Rises

31. Okt. 2024, 21:51 UTC

Top News

Australian House Prices Rise 0.3% in October

31. Okt. 2024, 21:50 UTC

Wichtige Markttreiber

Intel Shares Rally on 3Q Revenue, Upbeat Outlook

31. Okt. 2024, 23:46 UTC

Top News

Boeing Makes Another Offer to End Machinists Strike -- WSJ

31. Okt. 2024, 23:23 UTC

Top News

JPMorgan to Pay $151 Million for Alleged Misleading Disclosures, Other Charges -- Update

31. Okt. 2024, 22:51 UTC

Top News

Ergebnisse

Intel Posts More Than $16 Billion Loss but Says Sales Outlook Is Improving -- 2nd Update

31. Okt. 2024, 22:48 UTC

Top News

Ergebnisse

Amazon Shares Rise on Robust Demand, Surge in AI Infrastructure Spending -- WSJ

31. Okt. 2024, 22:40 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Strike Should Consider Selling Assets to Hancock -- Market Talk

31. Okt. 2024, 22:29 UTC

Ergebnisse

Macquarie Lifts Dividend, Extends Buyback After 1H Profit Rises -- Update

31. Okt. 2024, 21:59 UTC

Ergebnisse

Macquarie Lifts Dividend, Extends Buyback After 1H Profit Rises

31. Okt. 2024, 21:57 UTC

Market Talk

Ergebnisse

Intel Making Progress on $10B Cost Savings Push -- Market Talk

31. Okt. 2024, 21:55 UTC

Top News

Ergebnisse

Intel Posts More Than $16 Billion Loss but Says Sales Outlook Is Improving -- Update

31. Okt. 2024, 21:41 UTC

Top News

Ergebnisse

Chevron Could Rebound After a Middling Year -- Barrons.com

31. Okt. 2024, 21:39 UTC

Ergebnisse

Macquarie: Markets-Facing Activities A$1.4 Bln in Profit Contribution in 1H, Down 10% on Year

31. Okt. 2024, 21:39 UTC

Ergebnisse

Macquarie: Annuity-Style Activities A$1.6 Bln in Profit Contribution, Up 25% on Year

31. Okt. 2024, 21:38 UTC

Ergebnisse

Apple Beats September-Quarter Targets On iPhone, Services -- IBD

31. Okt. 2024, 21:36 UTC

Ergebnisse

Macquarie: Continues to Maintain Cautious Stance With Conservative Approach to Capital, Funding and Liquidity

31. Okt. 2024, 21:35 UTC

Ergebnisse

Macquarie: Has Acquired About A$1 Bln in Shares Through Buyback Program as of End-Oct

31. Okt. 2024, 21:35 UTC

Ergebnisse

Macquarie: Up to A$2 Bln Share Buyback Announced Last Year is Extended for 12 Months

31. Okt. 2024, 21:33 UTC

Ergebnisse

Macquarie: 1H Performance Also Driven by Further Progress in Digitalization in Banking and Financial Services

31. Okt. 2024, 21:33 UTC

Ergebnisse

Macquarie: Improved Performance in 1H Underpinned by Improved Realizations in Macquarie Asset Management

31. Okt. 2024, 21:31 UTC

Ergebnisse

Macquarie: Bank CET1 Level 2 Ratio 12.8%

31. Okt. 2024, 21:31 UTC

Ergebnisse

Macquarie: Financial Position Comfortably Exceeds Regulatory Minimum Requirements

31. Okt. 2024, 21:30 UTC

Ergebnisse

Macquarie: Assets Under Management A$917 Bln at End-Sept, Up 3% on Year

31. Okt. 2024, 21:29 UTC

Ergebnisse

Macquarie: International Income 65% of Total Income in 1H

Peer-Vergleich

Kursveränderung

Karyopharm Therapeutics Inc Prognose

Kursziel

By TipRanks

415.48% Vorteil

12-Monats-Prognose

Durchschnitt 4.33 USD 415.48%

Hoch 7 USD

Tief 2 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Karyopharm Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

6 ratings

Buy

Halten

Sell

Basierend auf 6 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Karyopharm Therapeutics Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

0.8423 / N/AUnterstützung & Widerstand

Recent bullish events outweigh bearish events.

Bullish events outweigh bearish events.

Bearish events outweigh bullish events.

Stimmung

By Acuity

93 / 389 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Karyopharm Therapeutics Inc

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. It is focused on the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (CRM1). Its lead compound, XPOVIO (selinexor), is marketed in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). NEXPOVIO (selinexor), the brand name for XPOVIO in Europe, in combination with dexamethasone to treat adult patients with multiple myeloma. It is also developing treatments for other diseases.